# Bloomberg (United States)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/bloomberg-united-states/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 77.9 |
| Citations | 772,734 |
| City | New York |
| Country | US |
| Description | Bloomberg (United States) is a research organisation in New York, US. OpenAlex records 6,044 works and 772,734 citations for it. 1,069 researchers list it as their most recent affiliation. |
| Homepage | http://www.bloomberg.com/company/ |
| OpenAlex ID | https://openalex.org/I1299907687 |
| Region | New York |
| Researchers | 1,069 |
| ROR ID | https://ror.org/02rdpzb15 |
| Type | company |
| Wikidata ID | https://www.wikidata.org/wiki/Q13977 |
| Works | 6,044 |

## University collaborators

- [Johns Hopkins University](https://scholariq.org/institutions/johns-hopkins-university/)
- [Sidney Kimmel Comprehensive Cancer Center](https://scholariq.org/institutions/sidney-kimmel-comprehensive-cancer-center/)

## University papers

Showing 12 of 133.

- [Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer](https://scholariq.org/papers/safety-activity-and-immune-correlates-of-anti-pd-1-antibody-in-cancer/)
- [Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-versus-chemotherapy-for-pd-l1-positive-non-small-cell-lung-cancer/)
- [PD-1 Blockade in Tumors with Mismatch-Repair Deficiency](https://scholariq.org/papers/pd-1-blockade-in-tumors-with-mismatch-repair-deficiency/)
- [Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-nonsquamous-non-small-cell-lung-cancer/)
- [Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-squamous-cell-non-small-cell-lung-cancer/)
- [Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer](https://scholariq.org/papers/safety-and-activity-of-anti-pd-l1-antibody-in-patients-with-advanced-cancer/)
- [Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade](https://scholariq.org/papers/mismatch-repair-deficiency-predicts-response-of-solid-tumors-to-pd-1-blockade/)
- [An Integrated Genomic Analysis of Human Glioblastoma Multiforme](https://scholariq.org/papers/an-integrated-genomic-analysis-of-human-glioblastoma-multiforme/)
- [Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer](https://scholariq.org/papers/paclitaxel-carboplatin-alone-or-with-bevacizumab-for-non-small-cell-lung-cancer/)
- [Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies](https://scholariq.org/papers/detection-of-circulating-tumor-dna-in-early-and-late-stage-human-malignancies/)
- [Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses](https://scholariq.org/papers/core-signaling-pathways-in-human-pancreatic-cancers-revealed-by-global-genomic/)
- [Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline](https://scholariq.org/papers/management-of-immune-related-adverse-events-in-patients-treated-with-immune/)

## University researchers

- [Julie R. Brahmer](https://scholariq.org/researchers/julie-r-brahmer/)
- [Patrick M. Forde](https://scholariq.org/researchers/patrick-m-forde/)
- [Janice Bowie](https://scholariq.org/researchers/janice-bowie/)

## University top topics

Showing 8 of 24.

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Galaxies: Formation, Evolution, Phenomena](https://scholariq.org/topics/galaxies-formation-evolution-phenomena/)
- [Stellar, planetary, and galactic studies](https://scholariq.org/topics/stellar-planetary-and-galactic-studies/)
- [Astronomy and Astrophysical Research](https://scholariq.org/topics/astronomy-and-astrophysical-research/)
- [Astrophysics and Star Formation Studies](https://scholariq.org/topics/astrophysics-and-star-formation-studies/)
- [Cardiovascular Health and Risk Factors](https://scholariq.org/topics/cardiovascular-health-and-risk-factors/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.